Geode Capital Management LLC Sells 66,974 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Geode Capital Management LLC decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 2.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,045,361 shares of the biotechnology company’s stock after selling 66,974 shares during the quarter. Geode Capital Management LLC owned approximately 2.00% of Heron Therapeutics worth $6,062,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Heron Therapeutics during the 2nd quarter valued at about $27,000. Cutter & CO Brokerage Inc. bought a new stake in Heron Therapeutics during the third quarter valued at approximately $39,000. Y Intercept Hong Kong Ltd purchased a new stake in Heron Therapeutics during the third quarter valued at approximately $39,000. B. Riley Wealth Advisors Inc. bought a new position in Heron Therapeutics in the second quarter worth approximately $41,000. Finally, Sei Investments Co. purchased a new position in shares of Heron Therapeutics during the 2nd quarter worth $44,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on HRTX. Needham & Company LLC restated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 4th. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday.

Heron Therapeutics Price Performance

HRTX opened at $1.66 on Friday. The company has a 50 day simple moving average of $1.51 and a two-hundred day simple moving average of $2.07. The firm has a market cap of $252.48 million, a P/E ratio of -9.22 and a beta of 1.60. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to the consensus estimate of $36.40 million. During the same period in the prior year, the company posted ($0.17) EPS. Equities analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.